1. Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma
- Author
-
Emad Matanes, Neta Eisenberg, Cristina Mitric, Amber Yasmeen, Sara Ismail, Oded Raban, Tal Cantor, David Knigin, Susie Lau, Shannon Salvador, Walter Gotlieb, and Liron Kogan
- Subjects
Aged, 80 and over ,Sentinel Lymph Node Biopsy ,Lymphadenopathy ,Obstetrics and Gynecology ,Endometrial Neoplasms ,Oncology ,Humans ,Lymph Node Excision ,Female ,Lymph Nodes ,Sentinel Lymph Node ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
ObjectiveWe aimed to evaluate the surgical and oncological outcomes of elderly patients with intermediate to high-risk endometrial cancer undergoing staging with sentinel lymph node (SLN) sampling and pelvic lymphadenectomy.MethodsWe conducted a retrospective study of elderly (>65-year-old) patients diagnosed with endometrial cancer between December 2007 and August 2017. These patients had been treated at a single center in Montreal, Canada. We compared the surgical and oncological outcomes of three cohorts undergoing surgical staging in non-overlapping eras: 1) lymphadenectomy, 2) lymphadenectomy and SLN sampling, 3) SLN sampling alone. Using life tables, Kaplan-Meier survival curves and log-rank tests, we analyzed 2-year progression-free survival, overall survival, and disease-specific survival.ResultsOur study included 278 patients with a median age of 73 years (range; 65–91): 84 (30.2%) underwent lymphadenectomy, 120 (43.2%) underwent SLN sampling with lymphadenectomy, and 74 (26.6%) had SLN sampling alone. The SLN sampling alone group had shorter operative times with a median duration of 199 minutes (range, 75–393) compared with 231 (range, 125–403) and 229 (range, 151–440) minutes in the SLN sampling with lymphadenectomy and lymphadenectomy cohorts; respectively (pConclusionSentinel lymph node-based surgical staging is feasible and associated with better surgical outcomes and comparable oncological outcomes in elderly patients with intermediate and high-risk endometrial cancer.
- Published
- 2022
- Full Text
- View/download PDF